Adalimumab biosimilar - Amgen

Drug Profile

Adalimumab biosimilar - Amgen

Alternative Names: ABP-501; Adalimumab-atto; Amgevita; Amjevita

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Skin disorder therapies
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Ankylosing spondylitis; Crohn's disease; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis; Uveitis

Most Recent Events

  • 25 Oct 2017 Amgen's Adalimumab biosimilar is still at registration stage for Ankylosing spondylitis, Crohn's disease, Juvenile rheumatoid arthritis, Plaque psoriasis, Psoriatic arthritis, Rheumatoid arthritis and Ulcerative colitis in USA (SC)
  • 28 Sep 2017 Amgen enters into global settlement agreement with Abbvie related to patent litigation regarding Adalimumab biosimilar
  • 28 Sep 2017 Amgen plans to launch Adalimumab biosimilar in Europe on 16/10/2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top